Abstract:BACKGROUND O-6-methylguanine-DNA methyltransferase (MGMT) is a suicide enzyme that repairs the mispairing base O-6-methyl-guanine induced by environmental and experimental carcinogens. It can transfer the alkyl group to a cysteine residue in its active site and became inactive. The chemical carcinogen N-nitroso compounds (NOCs) can directly bind to the DNA and induce the O-6-methylguanine adducts, which is an important cause of gene mutation and tumorigenesis. However, the underlying regulatory mechanism of MGMT involved in NOCs-induced tumorigenesis, especially in the initiation phase, remains largely unclear. AIM To investigate the molecular regulatory mechanism of MGMT in NOCs-induced gastric cell malignant transformation and tumorigenesis. METHODS We established a gastric epithelial cell malignant transformation model induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or N-methyl-N-nitroso-urea (MNU) treatment. Cell proliferation, colony formation, soft agar, cell migration, and xenograft assays were used to verify the malignant phenotype. By using quantitative real-time polymerase chain reaction (qPCR) and Western blot analysis, we detected the MGMT expression in malignant transformed cells. We also confirmed the MGMT expression in early stage gastric tumor tissues by qPCR and immunohistochemistry. MGMT gene promoter DNA methylation level was analyzed by methylation-specific PCR and bisulfite sequencing PCR. The role of MGMT in cell malignant transformation was analyzed by colony formation and soft agar assays. RESULTS We observed a constant increase in MGMT mRNA and protein expression in gastric epithelial cell malignant transformation induced by MNNG or MNU treatment. Moreover, we found a reduction of MGMT gene promoter methylation level by methylation-specific PCR and bisulfite sequencing PCR in MNNG/MNU-treated cells. Inhibition of the MGMT expression by O-6-benzylguanine promoted the MNNG/MNU-induced malignant phenotypes. Overexpression of MGMT partially reversed the cell malignant transformation process induced by MNNG/MNU. Clinical gastric tissue analysis showed that MGMT was upregulated in the precancerous lesions and metaplasia tissues, but downregulated in the gastric cancer tissues. CONCLUSION Our finding indicated that MGMT upregulation is induced via its DNA promoter hypomethylation. The highly expressed MGMT prevents the NOCs-induced cell malignant transformation and tumorigenesis, which suggests a potential novel approach for chemical carcinogenesis intervention by regulating aberrant epigenetic mechanisms.

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

Implications of Advances in Studies of O6-Methylguanine-DNA- Methyltransferase for Tumor Prognosis and Treatment

O6-methylguanine DNA Methyltransferase is Upregulated in Malignant Transformation of Gastric Epithelial Cells Via Its Gene Promoter DNA Hypomethylation

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

Post-Transcriptional Regulation of O-6-Methylguanine-Dna Methyltransferase Mgmt in Glioblastomas

O6-methylguanine DNA Methyltransferase As a Promising Target for the Treatment of Temozolomide-Resistant Gliomas

The specific role of O 6 -methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.

The Specific Role of O6-methylguanine-DNA Methyltransferase Inhibitors in Cancer Chemotherapy

Personalized Chemotherapy Based on O6-methylguanine-DNA methyltransferase (MGMT) Expression Pattern for Glioma Patients

Proteomic and Metabolomic Analyses Illustrate the Mechanisms of Expression of the O6-methylguanine-DNA Methyltransferase Gene in Glioblastoma

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma

MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

Clinical Response of O(6)-methylguanine-DNA Methyltransferase Levels to 1,3-(2-chloroethyl)-1-nitrosourea Chemotherapy in Glioma Patients.

Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review

[Individualized Chemotherapy Based on Drug Sensitivity and Resistance Assay and MGMT Protein Expression for Patients with Malignant Glioma--analysis of 42 Cases].

Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6 -methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen